Literature DB >> 569246

Scleroderma (progressive systemic sclerosis): progress and course based on a personal series of 118 cases.

A J Barnett.   

Abstract

A follow-up study has been made of a personal series of 118 cases of patients with scleroderma (progressive systemic sclerosis) followed for periods up to 25 years. These were classified according to the early distribution of skin changes as Type 1 (skin changes in fingers only), 48 cases; Type 2 (skin changes beyond the fingers but mainly in extremities), 47 cases; and Type 3 (diffuse), 19 cases, and atypical, four cases. Eighty per cent of the total series have survived five years, and 68% have survived 10 years. Survival is related to the type of scleroderma, being much better for Types 1 and 2 (acrosclerotic) than for Type 3 (diffuse). Actual compared with expected survival rate was better for younger than for older patients and for females than for males. Although the disease type gives an indication of survival in general, the caution must be used in the individual cases, as the course of the disease is very variable even in patients of the same type, and is subject to remission and relapse.

Entities:  

Mesh:

Year:  1978        PMID: 569246     DOI: 10.5694/j.1326-5377.1978.tb131413.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  17 in total

1.  Systemic sclerosis in the elderly.

Authors:  L Czirják; Z Nagy; G Szegedi
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 2.  Scleroderma and survival.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

3.  Predictors of survival in 171 patients with systemic sclerosis (scleroderma).

Authors:  Z Nagy; L Czirják
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

Review 4.  Epidemiology of scleroderma.

Authors:  A J Silman
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

5.  Spontaneous increase of transforming growth factor beta production by bronchoalveolar mononuclear cells of patients with systemic autoimmune diseases affecting the lung.

Authors:  Y Deguchi
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

6.  Immunosuppression for interstitial lung disease in systemic sclerosis - novel insights and opportunities for translational research.

Authors:  Marie Hudson; Russell Steele; Murray Baron
Journal:  J Cell Commun Signal       Date:  2012-08-03       Impact factor: 5.782

Review 7.  [Systemic sclerosis - diagnosis and classification].

Authors:  E Genth; T Krieg
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

8.  Differences in presentation of younger and older systemic sclerosis patients in clinical trials.

Authors:  H H Weng; V K Ranganath; M Oh; G S Park; D Khanna; P J Clements; J R Seibold; D A Elashoff; D E Furst
Journal:  Clin Exp Rheumatol       Date:  2010-11-03       Impact factor: 4.473

9.  Scl-95/100: doublet of endothelial marker autoantigens in progressive systemic sclerosis.

Authors:  F Alderuccio; A J Barnett; J H Campbell; J S Pedersen; B H Toh
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

10.  Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.

Authors:  M Vayssairat; N Baudot; N Abuaf; C Johanet
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.